Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +6.98%3 Equity-to-Asset is 0.00 as of . 20. GuruFocus rates XGHA:IIL with a GF Score™ of 3/100. Among 1,006 Drug Manufacturers companies, Intravenous Infusions ranks worse than 99403.48% on this metric.
The historical rank and industry rank for Intravenous Infusions's Equity-to-Asset or its related term are showing as below:
XGHA:IIL's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.61 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Intravenous Infusions Equity-to-Asset Related Terms
Intravenous Infusions Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Intravenous Infusions's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Equity-to-Asset Chart
Intravenous Infusions Annual Data
Trend
Equity-to-Asset
Intravenous Infusions Semi-Annual Data
Equity-to-Asset
XGHA:IIL vs PTLF, PCYN, YBAO: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Intravenous Infusions's Equity to Asset Ratio for the fiscal year that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions (XGHA:IIL) has a Equity-to-Asset of 0.00 as of . 20. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 1006 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Equity-to-Asset too high?
Intravenous Infusions' current Equity-to-Asset is 0.00. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Intravenous Infusions has a GF Score™ of 3/100, reflecting its overall financial health beyond just this single metric.
How does Intravenous Infusions' Equity-to-Asset compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 1006 companies for Equity-to-Asset. This places Intravenous Infusions in the lower half of its industry. The industry median Equity-to-Asset is 0.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. Intravenous Infusions' overall GF Score™ is 3/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Equity-to-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
3GF Score
Get the complete analysis for XGHA:IIL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
